<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>Pharos Discovery</title><description>Scientific journalism covering small molecules, biologics, clinical trials, and AI-driven drug discovery.</description><link>https://www.pharos-discovery.example/</link><language>en-us</language><item><title>An Oral GLP-1 That Survives the Gut Just Long Enough</title><link>https://www.pharos-discovery.example/articles/oral-glp1-permeation-enhancer-phase2/</link><guid isPermaLink="true">https://www.pharos-discovery.example/articles/oral-glp1-permeation-enhancer-phase2/</guid><description>Isthmus Biosciences reports Phase 2 results for ISX-220, an oral GLP-1 receptor agonist that uses a transient permeation enhancer rather than a reformulated peptide to achieve meaningful bioavailability — with weight loss approaching that of injectable semaglutide at 36 weeks.</description><pubDate>Wed, 21 Oct 2026 00:00:00 GMT</pubDate><category>Clinical Trials</category><author>Dana Okafor</author></item><item><title>A Generative Model Designed This KRAS Inhibitor. It&apos;s Now in Patients.</title><link>https://www.pharos-discovery.example/articles/ai-designed-kras-g12d-inhibitor/</link><guid isPermaLink="true">https://www.pharos-discovery.example/articles/ai-designed-kras-g12d-inhibitor/</guid><description>Aldebaran Therapeutics has advanced ALD-9102, a covalent KRAS G12D inhibitor generated by a structure-conditioned diffusion model, into a Phase 1 trial in pancreatic and colorectal cancer — one of the fastest generative-to-clinic timelines reported for a small molecule.</description><pubDate>Thu, 03 Sep 2026 00:00:00 GMT</pubDate><category>AI in Drug Discovery</category><author>Marcus Webb</author></item><item><title>A Drug Designed to Mimic the Body&apos;s Own Rhythm Moves Into Phase 3</title><link>https://www.pharos-discovery.example/articles/pulsatile-fxr-agonist-linafexor/</link><guid isPermaLink="true">https://www.pharos-discovery.example/articles/pulsatile-fxr-agonist-linafexor/</guid><description>A newly reported FXR agonist, linafexor, is designed to clear the body within an hour of dosing — mimicking the natural, pulsatile rhythm of bile acid signalling that earlier long-acting FXR drugs disrupted.</description><pubDate>Thu, 16 Jul 2026 00:00:00 GMT</pubDate><category>Small Molecules</category><author>Priya Ramanathan, PhD</author></item></channel></rss>